Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented Pharma Company with presence in 55 countries. Indoco, a USD 161 million company, employs over 5500 people including 300 skilled scientists.
The company has 9 manufacturing facilities, out of which 6 are for finished dosages and 3 for APIs, supported by a state-of-the-art R&D centre at Rabale, Navi Mumbai. The facilities have been approved by various regulatory authorities such as, USFDA, UK-MHRA, SUKL-Czech Republic, Cofepris – Mexico, TGA-Australia, JAZMP- Slovenia, MCC-South Africa, NDA-Uganda, TFDA-Tanzania, SBD-Yemen, MOH-Ukraine, PPB-Kenya and FDA-Ghana.
Indoco develops, manufactures and distributes a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from over 3,10,000 doctors in India. Indoco’s 9 domestic marketing divisions cater to different therapeutic segments, including Respiratory, Anti-Infectives, Dental Care, Pain Management, Gastroenterology, Opthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, ATM, Oxipod, Cital, Sensoform, Cloben-G, Sensodent – KF, Karvol Plus, Glychek, Vepan, Tuspel Plus, Flamar, etc.
Indoco has carved a place for itself in the international arena and is exporting a number of generic products in the Regulated and Emerging Markets. The Company’s products are distributed in over 55 countries across the globe, including USA and EU. Indoco’s branded formulations are promoted in Emerging Markets of South East Asia, Africa, Latin America and CIS countries. The Company participates in various tenders floated by authorities from different countries. Indoco has major tie-ups with big generic companies and works in close coordination with its customers for leveraging core competencies.
AnaCipher, Indoco’s Analytical Service Division has been carved to serve customers for their analytical resear
